Thu Sep 19 06:23:17 UTC 2024: ## Korro Bio (KRRO) Stock Receives “Buy” Rating from HC Wainwright, Target Price Set at $100

**New York, NY – September 19, 2024** – Korro Bio (NASDAQ: KRRO), a biopharmaceutical company focused on genetic medicine for rare and prevalent diseases, saw its stock receive a “buy” rating reiteration from research analysts at HC Wainwright. The firm also set a price objective of $100.00, suggesting a potential upside of 172.26% from the stock’s current price.

This optimistic outlook for Korro Bio is shared by other analysts. William Blair initiated coverage on the company with an “outperform” rating and a $180.00 target price, while Royal Bank of Canada maintained an “outperform” rating but lowered their target price from $105.00 to $95.00.

Overall, five analysts have given Korro Bio a “buy” rating, leading to a consensus rating of “Buy” and a consensus price target of $135.00 according to MarketBeat.com.

Korro Bio recently reported earnings for the quarter ending August 13th, posting ($2.43) earnings per share, slightly missing analysts’ expectations of ($2.39). Despite this, analysts predict Korro Bio will post -10.29 earnings per share for the current year.

The company’s lead product candidate, KRRO-110, is currently in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).

Institutional investors have shown interest in Korro Bio, with several large investors recently acquiring new stakes in the company, including Atlas Venture Life Science Advisors LLC, Monashee Investment Management LLC, 72 Investment Holdings LLC, Eventide Asset Management LLC, and Bank of New York Mellon Corp.

Overall, the recent positive ratings and analyst predictions suggest a strong outlook for Korro Bio and its efforts to develop innovative genetic medicines.

Read More